key: cord-0808332-mnk0c1qf
authors: Abd‐Elsalam, Sherief; Noor, Rasha A.; Badawi, Rehab; Khalaf, Mai; Esmail, Eslam S.; Soliman, Shaimaa; Abd El Ghafar, Mohamed S.; Elbahnasawy, Mohamed; Moustafa, Ehab F.; Hassany, Sahar M.; Medhat, Mohammed A.; Ramadan, Haidi Karam‐Allah; Eldeen, Maii A. S.; Alboraie, Mohamed; Cordie, Ahmed; Esmat, Gamal
title: Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study
date: 2021-06-07
journal: J Med Virol
DOI: 10.1002/jmv.27122
sha: 10ec64d20e5d3c4e4d53ae3fbfe5ac15940297b4
doc_id: 808332
cord_uid: mnk0c1qf

Researchers around the world are working at record speed to find the best ways to treat and prevent coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID‐19 infected patients. This was a randomized open‐label controlled study that included 164 patients with COVID‐19. Patients were randomized into two groups where Group 1 (Ivermectin group) included patients who received ivermectin 12 mg once daily for 3 days with standard care and Group 2 (control group) included patients who received standard protocol of treatment alone for 14 days. The main outcomes were mortality, the length of hospital stay, and the need for mechanical ventilation. All patients were followed up for 1 month. Overall, 82 individuals were randomized to receive ivermectin plus standard of care and 82 to receive standard of care alone. Patients in the ivermectin group had a shorter length of hospital stay (8.82 ± 4.94 days) than the control group (10.97 ± 5.28 days), but this was not statistically significant (p = 0.085). Three patients (3.7%) in each group required mechanical ventilation (p = 1.00). The death rate was three patients in the ivermectin group (3.7%) versus four patients (4.9%) in the control group without any significant difference between the two groups (p = 1.00). Although there was no statistically significant difference in any endpoints by ivermectin doses (12 mg/day for 3 days); there was an observed trend to reducing hospital stay in the ivermectin‐treated group.

severe cases should be monitored closely and sometimes need hospitalization. [3] [4] [5] Developing an effective therapy for COVID-19 infection is a complex process. Several immunotherapies, antiviral agents, and vaccines continue to be studied and developed as potential therapies for COVID-19. 4, 5 In March 2020, the WHO declared COVID-19 a global pandemic and an increasing number of cases of COVID-19 have been reported worldwide including in Egypt. The repurposing of commercially available COVID-19 pharmaceutical drugs has contributed to the production of hundreds of trials around the world. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Egyptian protocols to treat COVID-19 infection have mainly relied on many potential drugs, including, hydroxychloroquine, remdesivir, nitazoxanide, oseltamivir, favipiravir, lopinavir/ritonavir, and ivermectin. 11 Ivermectin, in vitro, is an inhibitor of SARS-CoV-2 which is able to lead to approximately 5000-fold reduction in viral RNA at 48 h. 10 This beneficial mechanism of ivermectin on the COVID-19 virus was not known until recently and it was thought that it behaved in the same manner as other viruses. The nuclear importation of virus and host proteins has been known to be inhibited. Virus integrase protein and importin (IMP) alpha/β1 heterodimer is responsible for nuclear import, further increasing infection are also, inhibited. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Ivermectin may be a safe, affordable, and readily available therapy of COVID-19. Therefore, the use of ivermectin warrants the rapid implementation of controlled clinical trials to assess the efficacy against SARS-CoV-2. 5 There were observational studies suggesting a beneficial effect of ivermectin in the treatment of COVID-19. So, we aimed in this study to evaluate the efficacy and safety of ivermectin in the treatment of COVID-19. 

The included patients were randomized using a computer random number generator to select random permuted blocks with a block size of eight and an equal allocation ratio. Sequentially numbered, opaque, sealed envelopes were used to ensure concealment. Three members of the study team (Soliman S, Mai Khalaf, and Eslam Saber Esmail) recruited, enrolled, and assigned participants to a computergenerated randomization sequence, held by an independent observer. During randomization, the proportional allocation of each clinical stratum was equalized in both groups. The included patients were first stratified according to their age (18-25, 26-40, 40-55, and >55), then by their gender (inside each stratum into males and females) and then their associated morbidities (absent and present).

We tried to keep the randomization equalized inside each stratum as much as we could.

Patients and physicians were aware of the assigned treatments. The patients were divided into two groups: Ivermectin tablets (Iverzine tablets, Unipharma) were used in the study.

Group 2: (Control group) 82 patients received standard protocol of treatment alone for 14 days. All patients were followed up for 1 month. All participants were submitted to the following demography: age, sex, weight, and height measurements and calculation of body mass index (BMI), history-associated symptoms and co-morbidities, clinical examination, and medication history. The following blood tests were done for all the patients in the trial including CBC analysis (WBCs-lymphocytes-PLTs-hemoglobin), liver function tests, Chest Xray, PCR for pharyngeal swab and ECG, computed tomography according to CO-RADS score. 26 The Egyptian MOH adopted a standard of care treatment protocol for patients with COVID-19. It included paracetamol, oxygen, fluids (according to the condition of the patient), empiric antibiotic, oseltamivir if needed (75 mg/12 h for 5 days), and invasive mechanical ventilation with hydrocortisone for severe cases if PaO 2 less than 60 mm Hg, O 2 saturation less than 90% despite oxygen or noninvasive ventilation, progressive hypercapnia, respiratory acidosis (pH < 7.3), and progressive or refractory septic shock. 11 Any side effects of the studied medication were assessed using by questionnaire done by the patients or their guardians.

The primary outcome was the assessment of clinical efficacy of ivermectin in the form of the analysis of all-cause mortality within 1 month after randomization and the secondary outcomes were the length of hospital stay, the need for mechanical ventilation, and the assessment of the safety of ivermectin.

The study was approved by the Tanta University faculty of medicine ethical committee and was registered on clinicaltrial.gov with registration number (NCT04403555). Informed consent was obtained from all participants in this study. Privacy of participants and confidentially of the data were assured. Risks and benefits were declared and any unexpected risks which appeared during the course of the research were cleared to participants and the ethical committee on time.

The primary analysis was done based on an intention-to-treat basis including all randomly assigned individuals. By the time of planning this study, there were very few pre-print pilot studies of ivermectin on humans (e.g., The study by Gorial et al. 16 died in the control group (p = 1.00) ( Table 2 ).

The univariable regression analysis showed that the patients' age, ALT, creatinine, ferritin, and CRP were independently related to the patients' mortality (p = 0.004, 0.001, < 0.001, 0.008, and < 0.001, respectively) ( Table 3) . Mild side effects were recorded; they were minimal in the ivermectin group with nausea in one patient and diarrhea in two patients. Ivermectin was not significantly related to the patients' mortality (p = 0.700).

The purpose of this randomized controlled trial was to determine the effectiveness and safety of ivermectin in COVID-19 therapy. Our study involved 164 patients who met the enrollment criteria and were enrolled and randomized to the ivermectin group (n = 82) or the control group (n = 82). The baseline demographic and clinical presentations in the two studied groups were similar without any significant difference. The laboratory parameters and the radiological findings were not significantly different either. In this study, the two groups did not show any statistically significant difference in clinical outcomes. Although there was no statistically significant difference, a trend to reducing the length of hospitalization was observed in the ivermectin. This favorable outcome of ivermectin was in accordance with Ahmed et al. 12 and Elgazzar et al., 13 who observed that early incorporation of ivermectin to the standard of care was very successful for the treatment of COVID-19 patients with shortened hospital stay duration; and was even associated with higher viral clearance. 12 Also, a pilot study by Chaccoura et al. 22 showed a tendency to lower viral loads in the ivermectin group as well as a tendency to lower IgG titers. This result may be due to its effect on the suppression of a number of inflammatory cytokines contributing to the "storm of cytokines" and then all disease squalls. 10 In a nonrandomized study by Gorial et al., 16 The ivermectin group did not show any significant difference either in the need for mechanical ventilation (p = 1.00) or the patients' mortality (p = 1.00) from the control group. In contrast, Elgazzar et al., 13 showed that ivermectin treatment was associated In conclusion; the usage of ivermectin did not achieve significance for any of the endpoints. However; there was an observed trend to reducing hospital stay in the ivermectin-treated group.

These findings may suggest using ivermectin as an add-on therapy to protocols used for the treatment of COVID-19. However, these results are needed to be validated in a larger prospective follow-up study.

All the authors declare that there are no conflict of interests.

Sherief 

WHO Declares Public Health Emergency for Novel Coronavirus

Mild or moderate COVID-19

Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease

Coronavirus disease 2019 treatment: a review of early and emerging options

Ivermectin and COVID-19: keeping rigor in times of urgency

Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import

Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan equine encephalitis virus replication

Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor ivermectin

Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study

The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Management Protocol for COVID-19 Patients. Ministry of health and population (MOHP), Egypt. Version 1.4

A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

Inhibitors of nuclear transport

Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)

Ivermectin treatment may improve the prognosis of patients with COVID-19

Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomized controlled study

Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients

Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens

Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, doubleblind, placebo-controlled, randomized clinical trial

Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study

Use of ivermectin in the treatment of Covid-19: a pilot trial

Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos

CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19 definition and evaluation

Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection

Tanta protocol for management of COVID-19: perspectives from a developing country

SARS-CoV-2: the path of prevention and control

Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study